GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Debt-to-Asset

RUA Life Sciences (FRA:AOHA) Debt-to-Asset : 0.09 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Debt-to-Asset?

RUA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.15 Mil. RUA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.37 Mil. RUA Life Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was €5.51 Mil. RUA Life Sciences's debt to asset for the quarter that ended in Sep. 2023 was 0.09.


RUA Life Sciences Debt-to-Asset Historical Data

The historical data trend for RUA Life Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences Debt-to-Asset Chart

RUA Life Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.04 0.05 0.08

RUA Life Sciences Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.07 0.08 0.09

Competitive Comparison of RUA Life Sciences's Debt-to-Asset

For the Medical Devices subindustry, RUA Life Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RUA Life Sciences's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Debt-to-Asset falls into.



RUA Life Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

RUA Life Sciences's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

RUA Life Sciences's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RUA Life Sciences  (FRA:AOHA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


RUA Life Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


RUA Life Sciences (FRA:AOHA) Business Description

Traded in Other Exchanges
Address
2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.

RUA Life Sciences (FRA:AOHA) Headlines

No Headlines